Dr. Brugarolas on unmet needs in the renal cell carcinoma treatment paradigm

According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).

Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.